Gilead Sciences (BUE:GILD) Accounts Payable : ARS524,035 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Accounts Payable?

Gilead Sciences's Accounts Payable for the quarter that ended in Mar. 2024 was ARS524,035 Mil.

Gilead Sciences's quarterly Accounts Payable declined from Sep. 2023 (ARS205,071 Mil) to Dec. 2023 (ARS198,550 Mil) but then increased from Dec. 2023 (ARS198,550 Mil) to Mar. 2024 (ARS524,035 Mil).

Gilead Sciences's annual Accounts Payable increased from Dec. 2021 (ARS71,198 Mil) to Dec. 2022 (ARS151,723 Mil) and increased from Dec. 2022 (ARS151,723 Mil) to Dec. 2023 (ARS198,550 Mil).

Gilead Sciences Accounts Payable Historical Data

The historical data trend for Gilead Sciences's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Accounts Payable Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

42,618.58

68,684.72

71,197.95

151,723.25

198,550.00

Gilead Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															123,863.85	149,280.00	205,070.71	198,550.00	524,035.01

Gilead Sciences Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Gilead Sciences Accounts Payable Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (BUE:GILD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.